Metropolitan Life Insurance Co. NY raised its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 8.6% during the first quarter, Holdings Channel reports. The fund owned 28,247 shares of the biotechnology company’s stock after buying an additional 2,233 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Heron Therapeutics were worth $424,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in HRTX. Legal & General Group Plc increased its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Heron Therapeutics during the first quarter worth $161,000. Old West Investment Management LLC purchased a new stake in Heron Therapeutics during the first quarter worth $206,000. Highbridge Capital Management LLC increased its stake in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock worth $206,000 after buying an additional 252 shares during the last quarter. Finally, Nationwide Fund Advisors increased its stake in Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock worth $330,000 after buying an additional 2,233 shares during the last quarter.

Heron Therapeutics, Inc. (NASDAQ HRTX) traded up 0.32% on Wednesday, reaching $15.45. The company’s stock had a trading volume of 46,631 shares. The firm’s 50-day moving average price is $15.42 and its 200-day moving average price is $14.64. Heron Therapeutics, Inc. has a 52-week low of $12.21 and a 52-week high of $21.55.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analyst estimates of $4.53 million. On average, equities analysts predict that Heron Therapeutics, Inc. will post ($3.73) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics, Inc. (HRTX) Shares Bought by Metropolitan Life Insurance Co. NY” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/heron-therapeutics-inc-hrtx-shares-bought-by-metropolitan-life-insurance-co-ny/1494929.html.

A number of equities research analysts have recently weighed in on the company. Jefferies Group LLC restated a “buy” rating on shares of Heron Therapeutics in a research report on Wednesday. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, August 10th. Cowen and Company set a $40.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $31.00 target price (up previously from $30.00) on shares of Heron Therapeutics in a research report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.